加载中
NASDAQHealthcareBiotechnology
最新数据
US$4.76
+US$0.05 · +1.06%
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
前收盘价
US$4.76
+US$0.05 · +1.06%
盘中时间采用ET。市场数据可能有所延迟。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日内区间
当前US$4.76
52周区间
当前US$4.76
盘中时间采用ET。市场数据可能有所延迟。
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
日内区间
当前US$4.76
52周区间
当前US$4.76
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 研究与开发 | 4893.6万 USD | 1736.3万 USD | 448万 USD | 717.2万 USD |
| 销售、一般及管理费用 | 1378.9万 USD | 530.5万 USD | 217.3万 USD | 270.2万 USD |
| 营业费用 | 6272.5万 USD | 2278.5万 USD | 741.5万 USD | 1136.3万 USD |
| 利息收入 | 513.9万 USD | 241.4万 USD | 142.3万 USD | 12万 USD |
| 折旧和摊销 | 3.6万 USD | 1.6万 USD | 9.7万 USD | 11万 USD |
| 营业利润 | −6272.5万 USD | −2278.5万 USD | −741.5万 USD | −1136.3万 USD |
| 净利润 | −5759.1万 USD | −2058.8万 USD | −720.8万 USD | −1356.4万 USD |
公司数据更新于 2026年10月11日。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI249.29万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF85.64万0.00%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB46.05万0.00%108.2亿 USD0.44%US$206.49+3.00%
iShares Micro-Cap ETFIWC18.87万0.01%13.17亿 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.17亿 USD0.73%US$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC2.19万—30.82亿 USD0.25%US$69.98+0.03%
U.S. Vector Equity Portfolio ETF Class SharesDXUV1.06万0.00%61.81亿 USD0.26%US$68.28+0.25%
Invesco Nasdaq Biotechnology ETFIBBQ7639.80.01%1.12亿 USD0.19%US$34.62+2.96%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVInvesco Nasdaq Biotechnology ETFIBBQAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
